Teleflex Q4 Revenue $567.3M, Below Expectations
Reports Q4 revenue $567.3M, consensus $912.57M. "Teleflex is in the midst of a transformation that optimizes our portfolio, creates a more focused medical technologies leader and positions our company for meaningful value creation opportunities going forward," said CEO Stuart Randle. "We have introduced financial guidance for 2026, which calls for mid-single-digit pro forma adjusted constant currency revenue growth. Our 2026 adjusted EPS outlook includes the full impact of stranded costs and excludes benefits from TS and MS agreements, share repurchase under our current $1B share repurchase authorization and intended debt paydown from the estimated $1.8B in after-tax proceeds from the strategic divestitures. We expect the TS and MS agreements to fully offset the $90M in stranded costs on an annualized basis. Furthermore, we are already taking action on reducing expenses when the TS and MS agreements roll off in the future, and are announcing an initial restructuring plan to mitigate $48M-$52M of annual stranded costs resulting from the divestitures. We expect our two strategic divestitures to close in the second half of 2026 and remain committed to using the majority of the net proceeds from the transactions to return significant capital to shareholders through share repurchases, while also reducing debt to enhance our financial flexibility and support future growth and value creation".
